■ Abstract The insulin resistance syndrome refers to a constellation of findings, including glucose intolerance, obesity, dyslipidemia, and hypertension, that promote the development of type 2 diabetes, cardiovascular disease, cancer, and other disorders. Defining the pathophysiological links between insulin resistance, the insulin resistance syndrome, and its sequelae is critical to understanding and treating these disorders. Over the past decade, two approaches have provided important insights into how changes in insulin signaling produce the spectrum of phenotypes associated with insulin resistance. First, studies using tissue-specific knockouts or tissue-specific reconstitution of the insulin receptor in vivo in mice have enabled us to deconstruct the insulin resistance syndromes by dissecting the contributions of different tissues to the insulin-resistant state. Second, in vivo and in vitro studies of the complex network of insulin signaling have provided insight into how insulin resistance can develop in some pathways whereas insulin sensitivity is maintained in others. These data, taken together, give us a framework for understanding the relationship between insulin resistance and the insulin resistance syndromes.
INTRODUCTION
The insulin resistance syndrome is a constellation of findings, including central obesity, glucose intolerance, dyslipidemia, and hypertension, that promotes the development of type 2 diabetes mellitus, cardiovascular disease, cancer, polycystic ovarian disease (PCOS), and nonalcoholic fatty liver disease ( Figure 1 ). Like type 2 diabetes and obesity, the insulin resistance syndrome (also called the metabolic syndrome, the dysmetabolic syndrome, or syndrome X) is increasing in prevalence with alarming rapidity, affecting 27% of adults in the United States (1) . Perhaps even more concerning is that up to 50% of severely obese children also have the insulin resistance syndrome (2) . Although much is known about the pathogenesis of obesity and type 2 diabetes, the molecular and pathophysiological links between insulin resistance, the various components of the insulin resistance syndrome, and their sequelae are not well understood.
In unraveling the complexity underlying these disorders, it is important to keep two concepts in mind. First, whereas insulin resistance is closely associated with Figure 1 The insulin resistance syndrome. Insulin resistance initially manifests itself as the constellation of symptoms that comprise the insulin resistance syndrome (shown in the orange circle). Ultimately, insulin resistance can evolve into a number of diseases (shown in the red circle).
alterations in glucose homeostasis, and assessments of insulin resistance usually focus on measurements of glucose or glucose uptake, insulin also regulates the synthesis and storage of fat, protein synthesis, and nonmetabolic processes such as cell growth and differentiation. Thus, alterations in glucose homeostasis are but one aspect of insulin resistance. Second, when we speak of insulin resistance, it is clear that not all insulin-regulated processes and tissues become equally resistant to insulin. Moreover, the hyperinsulinemia that evolves with insulin resistance may lead to increased insulin action in tissues or pathways that are not as resistant as those related to glucose metabolism. For example, hyperinsulinemia acting on the liver, kidney, and ovary leads to hypertriglyceridemia, increased sodium retention and hypertension, and hyperandrogenism, respectively (3) .
Over the past decade, two approaches have shed important insights into our understanding of how changes in insulin signaling produce the varied phenotypes associated with insulin resistance syndromes; these form the focus of this review. First, studies using tissue-specific knockouts or tissue-specific reconstitution of the insulin receptor in vivo in mice have enabled us to deconstruct the insulin resistance syndromes by dissecting the contributions of different tissues to the insulin-resistant state. Second, in vivo and in vitro studies of the complex network of insulin signaling have provided insight into how insulin resistance can develop in some pathways while insulin sensitivity is maintained in others. Finally, we discuss how these data impact our thinking about insulin resistance and the insulin resistance syndromes.
TISSUE-SPECIFIC ANALYSIS OF INSULIN ACTION AND INSULIN RESISTANCE
Classically, insulin resistance in muscle, liver, and fat has been viewed as central to the pathogenesis of the insulin resistance syndromes, particularly type 2 diabetes. To study the effects of insulin resistance in a particular tissue, investigators have used various strategies (3a,b; 4; 29; 33). Here we focus on studies in which tissuespecific insulin resistance has been created by conditional knockout of the insulin receptor using Cre-loxP technology (4) . In brief, a tissue-specific knockout of the insulin receptor (or other gene) can be produced by introducing two short bacterial DNA sequences called lox (locus of crossing-over) sites into the introns surrounding an essential exon or exons of the relevant gene (exon 4 in the case of the insulin receptor), producing a floxed allele. In the absence of the bacterial recombinase called Cre, this floxed allele behaves similarly to the wild-type allele. However, in the presence of Cre recombinase, these lox sites facilitate the excision of exon 4 of the insulin receptor and produce a missense mRNA with a premature stop codon. The resulting transcript encodes a small fragment of the insulin receptor that is incapable of insulin signaling and is rapidly degraded. By expressing the Cre recombinase in a single tissue, using various tissue-specific promoters to drive Cre recombinase expression, one can create mice with tissue-specific insulin resistance. Such mice have given us the powerful ability to redefine the nature of insulin resistance.
Liver Insulin Receptor Knockout
The liver plays a central role in glucose and lipid metabolism, and hepatic insulin resistance is thought to be largely responsible for the development of fasting hyperglycemia. To better understand the contribution of hepatic insulin resistance to the insulin resistance syndrome, the liver insulin receptor knockout (LIRKO) mouse was created using Cre recombinase driven by the albumin promoter (5).
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BIDDINGER KAHN By two months of age, LIRKO mice exhibit mild fasting hyperglycemia (132 versus 101 mg dl −1 in controls) and even more striking hyperglycemia in the fed state (363 versus 135 mg dl −1 in controls). These alterations in glucose tolerance appear to stem, in part, from the inability of insulin to suppress hepatic glucose production. Whereas insulin normally suppresses hepatic glucose production by more than 50% during a hyperinsulinemic-euglycemic clamp, this effect is lost in LIRKO mice. Hepatic insulin resistance is also characterized by increased expression of two key enzymes of gluconeogenesis, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase.
LIRKO mice are also markedly hyperinsulinemic, with insulin levels 20-fold greater than those of control animals. This is due to both the compensatory response of the β-cells of the pancreas, which undergo marked hypertrophy in LIRKO mice, and an impairment in insulin clearance due to the loss of receptor-mediated uptake and degradation in the liver. This leads to insulin resistance in nonhepatic tissues, i.e., tissues in which the insulin receptor has not been knocked out, which can be partially reversed by treating mice with streptozotocin, a toxin that destroys the β-cells of the pancreas (6) . The effects of pure hepatic insulin resistance, i.e., the physiology of the LIRKO mouse, are shown in Figure 2 .
Figure 2
Physiology of pure liver insulin resistance. Knockout of the insulin receptor (IR) in liver is associated with increased hepatic glucose production and decreased insulin clearance, leading to hyperinsulinemia and increased peripheral insulin resistance but decreased triglyceride secretion. This ultimately produces hyperglycemia but decreased triglycerides (TG) and free fatty acids (FFA).
Interestingly, although LIRKO mice exhibit hepatic insulin resistance and severe glucose intolerance, they have decreased levels of circulating free fatty acids and triglycerides (5) . This is due in part to the suppression of extrahepatic lipolysis, and hence of the release of free fatty acids, by the high insulin levels in these mice. Additionally, LIRKO mice have decreased rates of hepatic triglyceride secretion (6a), perhaps owing to the inability of hyperinsulinemia to drive triglyceride synthesis in the absence of hepatic insulin signaling. Thus, complete hepatic insulin resistance has beneficial effects on the serum lipid profile, which are not observed in states in which there is only partial insulin resistance.
LIRKO mice also reveal an unexpected role for insulin signaling in maintaining hepatic function. Histological examination of the livers of six-month old LIRKO mice reveals pale nodules with highly vacuolated cells and increased lipid accumulation but no frank fibrosis (5) . These histological changes are accompanied by a 50% decrease in serum albumin levels, suggesting a decrease in synthetic function. In addition, as LIRKO mice age, the impaired glucose tolerance resolves and the mice exhibit fasting hypoglycemia, most likely reflecting the decreased capacity of these livers for gluconeogenesis.
Muscle Insulin Receptor Knockouts
Glucose uptake into skeletal muscle accounts for the disposal of 70-90% of an oral glucose load. Furthermore, insulin resistance in muscle is one of the earliest defects in the development of type 2 diabetes (7, 8) . To clarify the role of muscle insulin resistance in the development of diabetes and the insulin resistance syndrome, muscle insulin receptor knockout (MIRKO) mice were made using Cre recombinase under the direction of the muscle creatine kinase promoter (4). These mice have >90% of the insulin receptor deleted in all skeletal muscle groups as well as in the heart. Surprisingly, despite exhibiting complete muscle insulin resistance, MIRKO mice have essentially normal blood glucose and insulin levels and a normal response to glucose tolerance testing. Under hyperinsulinemic-euglycemic clamp conditions, MIRKO muscle has a 75% decrease in insulin-stimulated glucose transport, a 73% decrease in insulin-stimulated glycolysis, and a 78% decrease in glycogen synthesis, indicating muscle insulin resistance (9). MIRKO mice also have a 10-30% decrease in muscle mass, indicating the role of insulin in protein synthesis and/or protection from protein breakdown (9).
Interestingly, adipose tissue from MIRKO mice shows an unexpected threefold increase in insulin-stimulated glucose transport in vivo, relative to controls (9). This increase in fat glucose uptake appears to be due to some unknown circulating factors released from MIRKO muscle because adipocytes isolated from MIRKO mice have rates of glucose uptake similar to controls in vitro. Consistent with this shift of substrates into adipose tissue, MIRKO mice have a 53% increase in epididymal fat pad weight and a 38% increase in whole-body fat content (4, 9, 10). MIRKO mice also have a 16% increase in free fatty acids and a 43% increase in serum triglycerides (9). Thus, MIRKO mice develop several major components of Figure 3 Physiology of pure muscle insulin resistance. Although knockout of the insulin receptor (IR) in muscle decreases muscle glucose uptake, glucose homeostasis overall is normal. This appears to be due to the secretion of muscle factors (MIRKO factors), which increase glucose uptake into fat. The excess flux of nutrients into fat increases adiposity. Also, through unknown mechanisms, MIRKO mice show an increase in serum triglycerides and free fatty acids (FFA). Thus, knockout of the muscle insulin receptor produces obesity and dyslipidemia, but not glucose intolerance.
the insulin resistance syndrome (mild obesity, hypertriglyceridemia, and increased free fatty acids) but do not develop glucose intolerance (Figure 3 ). MIRKO mice also fail to develop hyperinsulinemia, indicating that muscle insulin resistance alone is not sufficient to produce this compensatory response (4).
Fat Insulin Receptor Knockout
Classically, white adipose tissue has been considered a depot for energy storage, accounting for approximately 5-15% of an oral glucose load. However, the adipocyte is now also recognized as a major endocrine organ, secreting factors that play an important role in appetite regulation and energy homeostasis. To understand the potential role of insulin resistance in the fat in the insulin resistance syndrome, researchers knocked out the insulin receptor using Cre recombinase 129 under the aP2 promoter (11). aP2, a fatty acid-binding protein that is expressed primarily in adipocytes, is one of the most abundant proteins in fat.
In contrast to the muscle and liver forms of insulin resistance, pure fat insulin resistance in the fat insulin receptor knockout (FIRKO) mouse results in slightly improved glucose and lipid homeostasis relative to a normal mouse (11). Although fasted and fed blood sugar levels at two months of age are not significantly different in FIRKO mice as compared to their controls, fasting insulin levels are decreased by ∼45%, suggesting improved insulin sensitivity. The responses to glucose and insulin tolerance testing deteriorate by middle age (10 months) in control mice, but not in FIRKO mice. FIRKO mice also have decreased serum triglycerides without a change in serum free fatty acids.
Despite the surprising improvements in glucose homeostasis seen in vivo in FIRKO mice, adipocytes isolated from these mice show the expected defects in glucose and lipid metabolism, with a 90% decrease in insulin-stimulated glucose uptake and a corresponding decrease in insulin-stimulated incorporation of glucose into triglycerides, lactate, and carbon dioxide. Moreover, the ability of insulin to inhibit isoproterenol-induced lipolysis is blunted by approximately 50% (11).
Histological examination of FIRKO fat tissue also reveals an unexpected alteration in adipocyte morphology (11). In wild-type tissue, adipocyte size is normally distributed, with a median diameter between 75 μm and 100 μm. In FIRKO mice, on the other hand, there is a bimodal distribution of adipocytes, with one population of cells having a diameter of <75 μm and the other having a diameter >100 μm. This alteration in fat morphology is not due to differences in knockout efficiency, as both the large and small fat cells show almost complete ablation of insulin receptor expression. It seems instead to stem from some intrinsic heterogeneity in the fat cell response to the loss of insulin signaling. Thus, microarray and proteomics analysis show changes that correlate with both cell size and with changes in insulin signaling. Hence, both large and small FIRKO cells exhibit a decrease in interferon-γ and tumor necrosis factor (TNF)-α as a result of the loss of insulin signaling. By contrast, small adipocytes from both normal and FIRKO mice have decreased expression of enzymes important in lipid and energy metabolism, including fatty acid synthase, and of transcription factors such as C/EBPδ; small FIRKO adipocytes also have a decrease in C/EBPα (12, 13). This suggests that knockout of the insulin receptor unmasks some previously unrecognized intrinsic heterogeneity in white adipose tissue.
One of the most striking features of pure insulin resistance in fat is that rather than leading to development of insulin resistance syndrome, it creates resistance to this disorder (11). Thus, relative to control mice, FIRKO mice eat the same amount and yet have a 50% decrease in both brown and white adipose tissue and a 25% decrease in weight. These differences become even more profound when control and FIRKO mice are put on a high-fat diet or are treated with gold thioglucose, a hypothalamic toxin that causes severe hyperphagia (11, 14) .
Leanness and caloric restriction in mammals and defects in insulin signaling in lower organisms are associated with increased longevity (15-19). FIRKO mice are Figure 4 Physiology of pure adipocyte insulin resistance. Knockout of the insulin receptor (IR) in adipocytes decreases glucose uptake into fat and changes adipocyte morphology and gene and protein expression. This produces a more favorable adipokine profile, with increased leptin, adiponectin, and other adipocyte-derived factors (FIRKO factors), which protect against obesity, glucose intolerance, and dyslipidemia while increasing life span. lean and have insulin signaling defects in fat but are not calorically restricted. Thus, it was important to ask whether these lean mice, which eat more, have normal, increased, or decreased lifespans. In fact, FIRKO mice have an 18% increase in median lifespan compared to control mice (14), and at 30 months of age, when half of the control mice have died, more than 80% of FIRKO mice are still living. This suggests that leanness, even in the absence of reduced caloric intake, can promote longevity. This may also suggest some beneficial effect of insulin resistance that has allowed this trait to survive in evolution.
Although the exact mechanisms that produce these beneficial effects in FIRKO mice remain unknown, one intriguing hypothesis is that insulin resistance in the fat cell alters the complement of hormones elaborated by the adipocyte (Figure 4 ). For example, fat tissue is known to secrete leptin and adiponectin, hormones that improve insulin sensitivity, as well as resistin and inflammatory cytokines, such as TNF-α and interleukin-6, which promote insulin resistance. In support of this theory, adiponectin and leptin levels are increased and TNF-α expression in fat is decreased in these mice (11, 12).
β-Cell Insulin Receptor Knockout
One of the key features of diabetes is the development of β-cell failure. In type 2 diabetes, this is specifically characterized by a loss of glucose-stimulated insulin secretion as compared to the effects of other secretagogues. To understand the potential role of insulin signaling in this process, β-cell insulin receptor knockout (βIRKO) mice were created using Cre recombinase expression driven by the rat insulin promoter, which produces a near-complete knockout of insulin receptors in β-cells (20).
Prior to weaning, βIRKO mice have normal fasting and fed blood sugar levels (20). However, by two months of age, they develop an abnormal response to glucose tolerance testing, which further worsens with age. This defect is due to a loss of first-phase insulin secretion in response to glucose, whereas insulin secretion in response to arginine is normal. Also, by four months of age, βIRKO islets are significantly smaller than normal and have a 30% decrease in insulin content. This defect in β-cell growth is even more dramatic when βIRKO islets are subjected to an insulin-resistant, hyperinsulinemic state (R.N. Kulkarni, personal communication).
These studies highlight the potential importance of insulin signaling in the β-cell in the pathogenesis of type 2 diabetes. Indeed, the βIRKO mouse recapitulates one of the earliest defects found in patients with type 2 diabetes: impaired firstphase insulin secretion in response to glucose, but normal insulin secretion in response to other secretagogues. Insulin resistance in the β-cell may also contribute to the failure of type 2 diabetics to compensate fully for insulin resistance in other tissues by increasing β-cell mass. Although further studies are needed to determine the role of insulin resistance in the β-cell in humans, it is interesting to note that islets taken from type 2 diabetic individuals show a marked decrease in mRNA for several insulin signaling molecules, suggesting that insulin resistance in the β-cell may indeed be an important component of this disease's pathogenesis (21).
Vascular Endothelium Insulin Receptor Knockout
Vascular disease is a major cause of morbidity associated with the insulin resistance syndrome. Alterations in insulin signaling in the vascular endothelium may contribute to atherogenesis or to abnormal blood vessel proliferation. Also, insulin signaling in the endothelium may play a role in maintaining glucose homeostasis by promoting vasodilation, thus enhancing glucose delivery to muscle (22, 23) . Through the use of the Tie2 promoter-enhancer, which is expressed only in vascular endothelial cells and the endocardial cushion, to drive expression of Cre recombinase, the insulin receptor was knocked out of the vascular endothelium (24). VENIRKO mice do not show any abnormalities in glucose homeostasis, and although they tend to have lower heart rates and blood pressure, these changes generally are not significant (24) . Surprisingly, however, VENIRKO mice have a 20% decrease in triglycerides as compared to control mice (24, 25). Another unexpected finding is that the retinal vasculature in VENIRKO mice is partially
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BIDDINGER KAHN protected against relative hypoxia in a neonatal oxygen-induced model of retinopathy used to study diabetic retinopathy. Thus, VENIRKO mice exposed to relative hypoxia have a 50-70% decrease in the size of avascular areas, neovascular tuft formation, and neovascular nuclei when compared to similarly treated control mice. Moreover, VENIRKO mice have blunted increases in vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), and endothelin-1 expression following hypoxia (25). Thus, ablation of the insulin receptor in the vascular endothelium protects against neovascularization and may also have effects on vascular hemodynamics.
Knockout and Knockdown of the Insulin Receptor in the Brain
Although the brain is the major site of glucose utilization in the basal state, it is not classically considered an insulin-sensitive tissue, as insulin does not acutely regulate glucose uptake into the brain. Nonetheless, the presence of insulin receptors has been demonstrated in a wide variety of brain regions, including the medial and lateral portions of the arcuate nucleus of the hypothalamus, the olfactory tract, the cerebellum, and others (26).
To study the effects of insulin resistance in the brain, researchers have used two approaches. First, neuronal insulin receptor knockout (NIRKO) has been accomplished by expressing the Cre recombinase under the promoter for nestin, an intermediate-filament protein expressed in neuroepithelial stem cells (27) . NIRKO mice have a >95% decrease in insulin receptor expression in the brain. Second, the insulin receptor has been knocked down in the hypothalamus using antisense technology.
KNOCKOUT OF THE NEURONAL INSULIN RECEPTOR
Relative to controls, female NIRKO mice have a 20% increase in food intake, a 10-15% increase in body weight, and a twofold increase in fat pad weight ( Figure 5 ) (27) . Although male NIRKO mice are not hyperphagic, they still have a 1.5-fold increase in fat pad weight relative to controls. On a high-fat diet, both sexes have increased weight gain relative to controls. NIRKO mice have normal fasting blood glucose levels and responses to glucose tolerance testing, but this is in the context of a mild hyperinsulinemia indicating whole-body insulin resistance (27) . NIRKO mice also have a 30% increase in serum triglycerides. Thus, insulin resistance in the brain produces several components of the insulin resistance syndrome, including mild obesity, hyperinsulinemia, and hypertriglyceridemia. In addition, insulin action in the brain plays a role in the control of reproductive function. NIRKO mice of both sexes have a decrease in fertility due to hypothalamic hypogonadism (27) . Female NIRKO mice have fewer antral follicles and corpora lutea in the ovaries. Similarly, male NIRKO mice have a 30% decrease in epididymal sperm count and a decrease in the number of Leydig cells. Both sexes exhibit low LH and FSH levels, and females show a supranormal response to the gonadotropin-releasing hormone (GnRH), consistent with
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Figure 5
Physiology of pure brain insulin resistance. Knockout of the insulin receptor in the brain results in hyperphagia and therefore obesity. It also leads to decreased gonadotropin secretion and hyperphosphorylation of tau, an early marker of neurodegenerative disease. Lack of insulin signaling in the hypothalamus also impairs the ability of insulin to suppress hepatic glucose production. Hence, neuronal insulin resistance produces obesity, hyperinsulinemia, and dyslipidemia while contributing to reproductive abnormalities and perhaps neurodegenerative disease. hypothalamic hypogonadism. Although it is well known that there exists an association between insulin resistance and polycystic ovarian disease (PCOS) and that multiple mechanisms may play a role in the development of PCOS, the potential role of neuronal insulin resistance in this syndrome remains unexplored.
Finally, a lack of insulin signaling in the brain produces some changes suggestive of early neurodegenerative disease. This includes a 3.5-fold increase in phosphorylation of the microtubule-associated protein, Tau. Hyperphosphorylated Tau is a major early manifestation in Alzheimer's disease. Moreover, cultured NIRKO neurons are resistant to the protective effects of insulin on apoptosis. Despite this, NIRKO mice have normal learning and memory and do not develop neurofibrillary tangles (28) .
KNOCKDOWN OF THE HYPOTHALAMIC INSULIN RECEPTOR
Mindful of the potential importance of the hypothalamus in mediating the central effects of insulin, researchers generated mice with knockdown of the insulin receptor in the hypothalamus (HIRKD) by injecting antisense oligodeoxynucleotides directed against the insulin receptor into the third ventricle (29) . HIRKD mice have an 80% decrease of the insulin receptor in the medial arcuate and habenular nuclei as compared to controls in which a scrambled oligodeoxynucleotide is similarly injected.
HIRKD mice show an increase in expression of the orexigenic peptides neuropeptide Y (NPY) and Agouti-related peptide (AgRP), a 50% increase in food intake, and a fourfold increase in subcutaneous fat, but curiously no significant increase in visceral adiposity (29) . HIRKD mice have normal serum glucose and insulin levels. However, under hyperinsulinemic-euglycemic clamp conditions, HIRKD mice have a lower glucose infusion rate that can be attributed to a 40% increase in hepatic glucose production, suggesting that insulin signaling in the hypothalamus regulates hepatic glucose output (29) . Consistent with this conclusion, it has recently been shown that hepatic vagotomy abolishes the ability of central insulin administration to suppress hepatic glucose production (30) .
How Tissues Act Together to Produce the Insulin Resistance Syndrome
Recently, several models have been created to understand how defects in multiple tissues may interact to produce the insulin-resistant phenotype. For example, when insulin receptors are knocked out in both muscle and fat, there are no changes in glucose or insulin levels, indicating that peripheral insulin resistance alone is not sufficient to produce impaired glucose tolerance or the insulin resistance syndrome in the mouse (P.G. Laustsen, S.J. Russell, L. Cui, A. Entingh-Pearsall, M. Holzenberger, et al., manuscript submitted). Likewise, adding insulin resistance in the muscle to insulin resistance in the β-cell improves rather than worsens glucose tolerance. The improvement appears to be due to the ability of MIRKO muscle to enhance insulin secretion from the β-cell and increase glucose uptake in nonmuscle tissues (31) . Thus, glucose tolerance in βIRKO-MIRKO doubleknockout mice is intermediate between those of βIRKO and MIRKO mice (31) . By contrast, when insulin receptors are knocked out simultaneously in the liver and β-cells, mice become markedly diabetic, indicating the importance of the liver and pancreas in the final pathogenesis of the diabetic state (R.N. Kulkarni, personal communication).
A similar conclusion has been reached in a model in which mice with a wholebody knockout of the insulin receptor are rescued by transgenic expression of the insulin receptor in selected tissues. Thus, whereas whole-body insulin receptor knockout mice (IRKO) develop perinatal lethal diabetic ketoacidosis, whole-body IRKO mice in which insulin receptor expression has been reconstituted in the liver, brain, and β-cells are viable, do not develop diabetes (at least in the majority of animals), and have normalized adipose tissue content, lifespan, and reproductive function (32, 33) . Whole-body IRKO mice with insulin receptor reconstitution limited to liver and pancreatic β-cells are also rescued from perinatal death but still develop lipoatrophic diabetes and die prematurely (33) .
Another combinatorial insulin resistance model has been created by intraperitoneal injection of antisense oligodeoxynucleotides against the insulin receptor (34). In these mice, insulin receptor expression is decreased by 95% in liver and 65% in fat tissue but is unchanged in the hypothalamus and muscle. Such mice have normal glucose, insulin, and leptin levels combined with a decrease in serum free fatty acids and glycerol.
These data, taken together, highlight the importance of insulin signaling in the brain, liver, and β-cells in maintaining glucose homeostasis. It also suggests that insulin resistance in fat and muscle is not detrimental to overall glucose homeostasis and is possibly beneficial in compensating for insulin resistance in the brain, liver, and β-cells.
INSULIN SIGNALING
Although the above studies are helpful in defining the contributions of different tissues to the insulin-resistant state, it is important to remember that the pure insulin resistance associated with ablation of the insulin receptor is only seen in rare, genetic states of insulin resistance, such as leprechaunism and the type A syndrome of insulin resistance (35, 36) . Most cases of insulin resistance are due to a combination of factors acting to create partial resistance in some, but not necessarily all, pathways of insulin action. Thus, some pathways may retain sensitivity to insulin, and the degree to which a particular pathway becomes resistant may vary from tissue to tissue. To understand better how different pathways develop varying degrees of insulin resistance, it is necessary to consider the molecular basis of insulin signaling and insulin resistance. Thus, we review below the insulin signaling network ( Figure 6 ) and how knockout of various components of the cascade can impact the insulin-resistant phenotype. We also examine the molecular mechanisms producing insulin resistance as well as the changes in signaling that occur in mouse models and human states of insulin resistance.
Proximal Insulin Signaling
Insulin signaling is triggered by the binding of insulin to its receptor in the plasma membrane of the cell. The insulin receptor is a heterodimeric complex consisting of two α-subunits, capable of insulin binding, and two β-subunits with intrinsic tyrosine kinase activity. Ligand binding of the α-subunits allows the β-subunits to transphosphorylate one another, further increasing their kinase activity (37, 38) .
Thus far, more than 10 substrates of the insulin receptor have been identified, of which 4 are structurally related and have been termed the insulin receptor substrate (IRS) proteins (39) (40) (41) (42) (43) . The IRS family members vary in molecular weight between 60 kDa and 180 kDa. Each contains a pleckstrin homology (PH) domain, a protein tyrosine-binding (PTB) domain, and numerous tyrosine residues that can undergo phosphorylation by the insulin receptor tyrosine kinase. The IRS proteins vary in their tissue distribution and subcellular localization (44) (45) (46) (47) (48) (49) . Other targets of Figure 6 The insulin signaling network. Insulin signaling impacts many cellular processes, including the metabolism of glucose, protein, and lipids, as well as cell growth and differentiation. Thus, the insulin signaling network is broad and complex. the insulin receptor tyrosine kinase include Shc, Cbl, p62dok, and Gab-1 (50) (51) (52) (53) (54) . Once phosphorylated, these substrates act as docking molecules for proteins that contain src homology region 2 (SH2) domains, which in turn become activated or associate with other downstream signaling molecules, setting off a complicated cascade of events. Although the details of the insulin signaling network continue to be elucidated, those pathways that are understood better are presented below. PHOSPHATIDYLINOSITOL 3-KINASE One of the key intermediates in the insulin signaling network is the class Ia forms of phosphatidylinositol 3-kinase (PI 3-kinase) (reviewed in References 55 and 56). Active PI 3-kinase exists as a heterodimer, consisting of a p110 catalytic subunit, of which there are three isoforms, and a regulatory subunit, of which there are eight known isoforms. The regulatory subunits are encoded by three genes, Pik3r1, Pik3r2, and Pik3r3. Pik3r1 encodes p85α, the ubiquitously expressed and most abundant regulatory subunit (57) . p85α contains multiple domains that may mediate interactions with other proteins, including a src homology region 3 (SH3) domain, a bcr homology domain flanked by two proline-rich regions, and two SH2 domains that flank the p110 catalytic subunitbinding region. The two SH2 regions of PI 3-kinase bind specific phosphotyrosinecontaining motifs, pYMXM and pYXXM, found in the IRS proteins. Pik3r1 can also be alternatively spliced to yield p55α (initially identified as AS53) and p50α (57) . These isoforms contain the same two SH2 domains and the p110-binding region; however, they lack the bcr domain, one of the proline-rich regions, and the SH3 domain found in p85α. Instead, p55α and p50α have novel N-terminal sequences of 34 and 6 amino acids, respectively. Additionally, these three isoforms can be alternatively spliced such that aspartate 605, located between the SH2 domains, is replaced by nine amino acids, adding two potential serine phosphorylation sites (58) . Pik3r2 encodes p85β, which is homologous to p85α, whereas Pik3r3 encodes p55γ (also known as p55PIK), which is similar to p55α. PI 3-kinase has multiple roles in signal transduction (59) . Its most important role in insulin signaling is in the phosphorylation of the phosphoinositides at the 3-position to produce PI-3P, PI-(3,4)P 2 , and PI-(3,4,5)P 3 , or PIP 3 . These molecules can bind to the PH domains of other signaling molecules, activating them or altering their subcellular location. A major target of the PI 3-phosphates is the AGC family of serine/threonine protein kinases, including PDK1 (PI-dependent kinase 1) and some of the atypical forms of protein kinase C (PKC). The importance of PI 3-kinase in insulin signaling is highlighted by studies showing that virtually all of insulin's effects on glucose transport, lipogenesis, and glycogenesis are abolished by either inhibitors or dominant-negative mutants of PI 3-kinase (55, 60) .
TARGETS OF PI 3-KINASE PI 3-kinase activates the serine/threonine kinase Akt (also known as protein kinase B, or PKB). This appears to occur by two means (55, 56) . First, PIP 2 and PIP 3 recruit Akt to the plasma membrane through its PH domain, thus bringing it into proximity with the kinase PDK1, which resides at the membrane. Second, the PI 3-phosphates, particularly PIP 3 , activate PDK1. Thus, PDK1 is able to phosphorylate and activate Akt.
Akt has numerous and diverse intracellular targets. It phosphorylates glycogen synthase kinase 3 (GSK3), deactivating it (61). Deactivation of GSK3 leads to derepression, i.e., activation, of glycogen synthase, which is normally inhibited by phosphorylation by GSK3. This results in a stimulation of glycogen synthesis. Akt also phosphorylates the transcription factor FOXO-1. Phosphorylation of FOXO-1 leads to its exclusion from the nucleus, preventing it from activating transcription of various genes, such as phosphoenolpyruvate carboxykinase and glucose 6-phosphatase, two important enzymes in gluconeogenesis (62) . Finally, Akt promotes insulin-stimulated glucose uptake, as stable expression of a constitutively active, membrane-bound form of Akt in 3T3-L1 adipocytes results in increased glucose transport and persistent localization of Glut4 to the plasma membrane (63) . PI 3-kinase also activates the atypical forms of PKC, including PKCλ and PKCζ. Like Akt, the atypical PKCs appear to be important in mediating insulin-stimulated glucose uptake. Overexpression of PKCζ or -λ results in increased translocation of the insulin-sensitive glucose transporter, Glut4, to the plasma membrane (64, 65) . Conversely, dominant-negative mutants of PKCλ inhibit insulin-stimulated glucose uptake (66) . Some recent studies have suggested that these atypical PKCs are more closely linked to IRS-1-mediated signaling in muscle and fat than to IRS-2-mediated signaling, although both IRS proteins activate PI 3-kinase (67). The exact mechanism by which this specificity occurs is unclear.
MAP KINASE PATHWAY Another major pathway for insulin signaling is the mitogen-activated protein (MAP) kinase pathway. Insulin stimulates tyrosine phosphorylation of the IRS proteins, Gab1, and Shc, allowing them to bind the SH2 domain of the adaptor molecule Grb2. Grb2 recruits the guanyl nucleotide-exchange protein, SOS, to the plasma membrane, where it can activate the G protein Ras. Ras then induces the sequential phosphorylation and activation of the serine/threonine kinases, Raf, MAP kinase-kinase (or MEK), and the MAP kinases ERK 1 and ERK 2. The MAP kinases can phosphorylate substrates in the cytoplasm or translocate to the nucleus to phosphorylate transcription factors such as Elk-1 (68) . MAP kinases are associated in particular with the proliferative effects of insulin, as pharmacological inhibitors and dominant-negative mutants of these proteins inhibit the stimulation of cell growth by insulin but have less impact on insulin's metabolic and anabolic effects (69) .
SREBP-1c
Whereas many of insulin's effects on the expression of genes in the glucose metabolic pathway are regulated by FOXO1, many of insulin's effects on lipogenesis appear to be mediated via the transcription factor sterol regulatory element-binding protein (SREBP)-1c. The SREBPs are a family of three nuclear transcription factors encoded by two genes (70) . SREBP-1c, the dominant isoform in liver and adipose, is capable of activating the entire program of monounsaturated fatty acid synthesis; it also appears to be involved in the regulation of gluconeogenic genes, although to a lesser extent than FOXO1 (71) . SREBP-1c also plays an important role in adipocyte differentiation (72) .
The SREBPs are subject to complex regulation at the transcriptional and posttranslational levels (70) . Their transcripts encode membrane-bound precursors, which are retained in the endoplasmic reticulum by Insig proteins. Sterol depletion causes dissociation of the Insig proteins, allowing the SREBPs to proceed to the Golgi apparatus, where the two proteases that cleave the SREBPs are located. Once the N-terminal fragment of SREBP is released from the membrane, it can translocate into the nucleus to activate transcription.
Several lines of evidence suggest that insulin directly regulates SREBP-1c. First, SREBP-1c transcript and nuclear protein are increased by insulin treatment in hepatocytes (73) . Second, streptozotocin treatment, which renders mice insulin deficient, results in a decrease in SREBP-1c (73) . Similarly, fasting, which also lowers insulin levels, decreases SREBP-1c (74) . Conversely, refeeding induces an exaggerated insulin response that is accompanied by an increase in SREBP-1c (74) . Third, transgenic overexpression of constitutively active SREBP-1c induces the entire complement of genes necessary for fatty acid synthesis and obviates the need for insulin, whereas dominant-negative forms of SREBP-1c prevent lipogenic gene expression even in the presence of insulin.
Insulin appears to increase SREBP-1c transcription, maturation, and activity. Insulin induces SREBP-1c transcription by activating the transcription factor, liver X receptor (LXR), which is known to bind the SREBP-1c promoter and activate its transcription in an insulin-dependent manner (79) . Induction of SREBP-1c transcript appears dependent on PI 3-kinase, through activation of PKCλ, although Akt has also been implicated (75) (76) (77) (78) . Insulin also suppresses expression of Insig2a, which is the predominant Insig transcript in the livers of fasted animals. Suppression of Insig2a allows SREBP precursors to be escorted to the Golgi apparatus and undergo activation (80) . Finally, insulin-stimulated phosphorylation of SREBP-1c mediated by GSK3 and ERK1/ERK 2 may modulate its activity (81, 82) .
mTOR Another important downstream target of Akt that plays a particularly important role in protein synthesis is the protein mTOR (mammalian target of rapamycin). Akt phosphorylates and inhibits TSC2, a component of the tuberous sclerosis heterodimer, which inhibits mTOR (83) (84) (85) . mTOR, in association with the protein raptor, regulates protein synthesis by phosphorylating and activating the p70 ribosomal S6 kinase (p70S6K). p70S6K phosphorylates the ribosomal S6 protein and thus increases ribosome biosynthesis. mTOR also phosphorylates PHAS-I, also known as eukaryotic translation initiation factor 4E-binding protein 1, enabling it to dissociate from elongation initiation factor 4E and increase translation of mRNAs with a highly structured 5 untranslated region. Interestingly, it has recently been shown that mTOR, in association with the protein rictor, can activate Akt by phosphorylating Ser473 directly and facilitating phosphorylation of Thr308 by PDK1 (86) .
Knockout of Components of the Insulin Signaling Pathway
Over the past decade, the exact roles of many of the signaling components in the insulin signaling network have been studied using genetic knockout strategies as well as knockdown strategies using RNA interference (RNAi) and antisense approaches. Although most of these studies have focused on the role of each of these pathways in the development of glucose intolerance and diabetes, knockout mice also give us some insight into the in vivo role of these proteins in lipid synthesis and cell growth, and help create a picture of how defects at different sites in the insulin signaling network may contribute to the spectrum of the insulinresistant phenotypes.
KNOCKOUTS OF THE PROXIMAL INSULIN SIGNALING COMPONENTS
Whereas complete knockout of the insulin receptor produces insulin resistance in all pathways, Figure 7 The effects of genetic ablation on glucose homeostasis. The PI 3-kinase portion of the insulin signaling network illustrates the complexity of insulin's metabolic signaling. There are four IRS proteins, five regulatory subunits of PI 3-kinase (with three more produced by alternative splicing), three catalytic units of PI 3-kinase, and three isoforms of Akt. Loss of a particular signaling molecule or isoform can have positive (green), slightly negative (orange), negative (red), or neutral (white) effects on glucose homeostasis. Gray denotes that the effects of deletion on glucose homeostasis are unknown.
leading to uncontrolled diabetes and death, knockout and knockdown of the IRS proteins in mice produce varying degrees of glucose intolerance and different types of insulin resistance syndromes (32) (Figure 7 ). Mice with a complete knockout of IRS-1 exhibit impaired glucose tolerance, increased serum triglycerides (presumably owing to a decrease in triglyceride clearance), and hypertension (87) . They also have severe, global growth retardation owing to a decrease in IGF-1-mediated signaling (88) . By contrast, IRS-2 knockout mice develop diabetes, which appears to be due to hepatic insulin resistance in addition to a defect in pancreatic β-cell growth and/or development (89, 90) . IRS-2 knockouts are also dyslipidemic and hypertensive (91) . Moreover, in a mouse model of atherosclerosis, IRS-2 knockout mice show increased neointima formation in response to injury (91) . IRS-2 knockout mice do not have global growth retardation but do have a decrease in the size of a few tissues, including certain neuronal cells and the islets of Langerhans (89, 90) .
Knockdowns of IRS-1 and IRS-2 using adenoviral-mediated delivery of siRNA, which primarily targets the liver, and not other tissues, produces more specific defects. Decreasing hepatic IRS-1 specifically reduces expression of glucokinase and produces a trend toward hyperglycemia but has no effect on hepatic lipids (92) . Knockdown of IRS-2, on the other hand, produces an increase in SREBP-1c and fatty acid synthase, as well as increased hepatic lipid accumulation, but no change in glucose tolerance (92) .
The exact role of other substrates in signaling is more difficult to discern. IRS-3 knockout mice appear entirely normal, whereas IRS-4 knockout mice have minimal abnormalities in glucose tolerance (93, 94) . By contrast, knockout of hepatic Gab-1, which can mediate signaling to the MAP kinase pathway, actually improves glucose tolerance and signaling through IRS-1 and IRS-2 (95), presumably by preventing inhibitory serine phosphorylation of the IRS proteins by the MAP kinases (see below). In cells in culture, a similar inhibitory effect has been ascribed to .
In some cases, combining defects in two proteins increases the severity of the phenotype. For instance, mice with knockdown of both IRS-1 and IRS-2 using adenoviral-mediated delivery of siRNA develop both glucose intolerance and hepatic steatosis (92) , and the whole-body double knockout is early-fetal lethal (97) . Mice with double knockout of IRS-1 and IRS-3 develop lipoatrophic diabetes and hence a more severe phenotype than either of the single knockouts (98) . By contrast, mice with double knockout of IRS-2 and IRS-3 resemble IRS-2 knockout mice and develop diabetes at a similar rate (99) . Thus, the degree of functional overlap exhibited by the IRS proteins is variable (99) .
KNOCKOUT OF PI 3-KINASE Disruption of the entire Pik3r1 gene, and hence of p85α, p55α, and p50α, results in death in mice a few weeks after birth, illustrating the importance of this gene for survival (100) . However, knockouts of individual isoforms of the regulatory subunit of PI 3-kinase are viable and paradoxically more insulin sensitive than normal mice. For example, knockout of only p85α (101) or heterozygous knockout of the Pik3r1 gene (102) results in mice with normal growth and improved insulin sensitivity. In the latter case, the heterozygous knockout can even prevent the development of diabetes in mice with other genetic defects, like those with a combined heterozygous knockout of the insulin receptor and IRS-1 (102) . Likewise, selective knockout of p55α and p50α results in mice with normal growth, decreased fat mass, and increased insulin sensitivity (103) . Finally, knockout of p85β alone also results in hypoinsulinemia, hypoglycemia, and improved insulin sensitivity (102a).
Although the basis for the improvement in insulin sensitivity has not been fully elucidated, quantitative studies have suggested that it may be due to more efficient signaling of PI 3-kinase. Thus, under normal conditions, the regulatory subunits are in excess of the catalytic subunits (104) . As a result, monomeric forms of the regulatory subunit, which are inactive in signaling, can compete with the active heterodimers for binding to the IRS proteins. Thus, reducing the concentration of regulatory subunits improves the ratio of regulatory to catalytic subunits and increases the efficiency of signaling. Conversely, increasing the concentration of regulatory subunits, as appears to occur in pregnancy, actually may result in insulin resistance (105) .
Deletion of the catalytic subunits of PI 3-kinase, on the other hand, produces insulin resistance (106) . Although homozygous knockout of either the p110α or the p110β catalytic subunit is embryonic lethal, double heterozygous p110α +/− p110β +/− mice are glucose intolerant, exhibiting mild fasting hyperinsulinemia and decreased IRS-associated PI 3-kinase activity upon insulin stimulation (106) (107) (108) . Interestingly, mice with knockout of the p110-γ form of the catalytic subunit, which is expressed in pancreatic islets, have a greater hypoglycemic response to insulin than do control mice. However, these mice also are impaired in glucose-stimulated insulin secretion and are thus mildly glucose intolerant (109).
KNOCKOUT OF AKT There are three isoforms of Akt encoded by three different genes. Knockout of Akt1, the ubiquitously expressed isoform of Akt1, produces a global defect in growth but essentially no alterations in glucose homeostasis (110) . Likewise, knockout of Akt3, which is expressed predominantly in the brain and testes, results in a reduction in brain size but no changes in glucose metabolism (111) .
By contrast, knockout of Akt2, which is expressed in pancreatic β-cells, skeletal muscle, and brown fat, results in glucose intolerance and hyperinsulinemia. Loss of Akt2 also impairs insulin-stimulated glucose uptake into muscle and decreases the ability of insulin to suppress hepatic glucose output (112) . Akt2 knockout mice also have increased serum triglycerides (113) and under some conditions develop β-cell failure and diabetes (113) . Interestingly, because Akt2 is expressed in platelets, Akt2 knockout mice also have defects in platelet aggregation and thrombus formation (114) .
A role for Akt in insulin secretion has been confirmed by creation of transgenic mice expressing a kinase-dead mutant of Akt specifically in β-cells (115) . Such mice have a defect in insulin exocytosis and eventually develop glucose intolerance. Conversely, mice overexpressing a constitutively active form of Akt in the liver become hypoglycemic, hypoinsulinemic, and, by mechanisms that are not clear, hypertriglyceridemic (116) .
KNOCKOUT OF THE MAPK PATHWAY Although the major effects of the MAP kinase pathway focus on cell growth, ERK1 knockout mice have a metabolic phenotype with decreased adiposity, owing to a decrease in the number of adipocytes (117) . When challenged with a high-fat diet, these mice, like FIRKO mice, are protected from obesity or glucose intolerance (11). Such findings are consistent with the importance of ERK1 signaling in adipogenesis.
KNOCKOUT OF SREBP-1c
Knockout of SREBP-1c does not alter serum insulin or glucose levels. However, mice lacking SREBP-1c have a 50% decrease in serum triglycerides and a 10% decrease in serum cholesterol (118) . On the other hand, transgenic mice expressing a constitutively active form of SREBP-1c develop hepatic steatosis, a finding associated with the insulin resistance syndrome in humans and mice (119) (120) (121) . Somewhat surprisingly, whereas SREBP-1c promotes adipocyte differentiation in vitro, mice expressing a constitutively active form of SREBP-1c only in adipose tissue have disordered differentiation of white and brown fat (122) . The little fat that accumulates in these mice has a histologically immature appearance. Perhaps because of an alteration in adipokine production, they also develop extremely high insulin levels, hepatic steatosis, diabetes, and elevated triglycerides, all of which can be reversed with leptin treatment (122, 123) .
Molecular Mechanisms of Insulin Resistance
The insulin signaling cascade is both complex and broad. At each step of the cascade, there appear to be several molecules or isoforms capable of transducing the signal, each with distinct but overlapping functions. For example, in the major pathway leading to the metabolic actions of insulin, the insulin receptor theoretically activates any of the 4 IRS proteins, which in turn activate 1 of 24 possible PI 3-kinase heterodimers, leading to activation of 1 of 3 Akt isoforms. Thus, even in these first three signaling steps in the metabolic pathway of insulin action, there are at least 288 combinations of signaling molecules. But this is not the only known pathway implicated in insulin action; moreover, there may be many additional players and pathways that have yet to be identified. Thus, the number of signaling combinations probably exceeds 1000. Theoretically, diminishing the activity of any single component of the insulin signaling cascade or any combination of components may produce a distinct type of insulin resistance with its own molecular signature.
At the molecular level, insulin resistance can be acquired through multiple mechanisms (Figure 8 ). First, important components of the insulin signaling cascade can be decreased by either increased degradation or by decreased transcription, as has been described for IRS-1 and IRS-2 (124) (125) (126) (127) . In this regard, many of the signaling components interact in such a way as to regulate one another. For example, recent studies have shown that SREBP-1c can suppress transcription of IRS-2, suggesting that increased stimulation of SREBP-1c can lead to a decrease in IRS-2 levels (128). Second, as noted above, if the regulatory subunits of PI 3-kinase are further increased, they can act as inhibitors of the normal dimeric form of the enzyme. Third, any of these components can undergo posttranslational modifications that decrease or increase its activity. For example, the insulin receptor and the IRS proteins can undergo serine phosphorylation by PKC, ERK, and the stress kinases, JNK and IKKβ (129) (130) (131) . Serine phosphorylation of the insulin receptor decreases its kinase activity. Serine phosphorylation of the IRS proteins impairs their ability to be tyrosine phosphorylated and increases their association with the 14-3-3 proteins, removing them from the insulin signaling cascade (132) .
Figure 8
Mechanisms that can produce insulin resistance. Multiple mechanisms exist for downregulating insulin signaling, such as decreased synthesis, increased degradation, inhibitory serine phosphorylation, interaction with inhibitory proteins, and alteration of the ratios of different signaling molecules.
Fourth, insulin resistance can be produced by the interaction of inhibitory proteins with components of the insulin signaling cascade. For example, the suppressors of cytokine signaling (SOCS) proteins, which are induced by inflammatory cytokines, bind to the insulin receptor and block its signaling (133, 134) . Finally, insulin resistance can be due to increases in the activity or amount of the enzymes that normally reverse insulin action, including the phosphotyrosine phosphatases, e.g., PTP1b, and the PIP 3 phosphatases, e.g., PTEN and SHIP (135, 136) .
Ultimately, the phenotype of insulin resistance will depend on the exact components affected and the exact tissues in which they are affected. For example, insulin resistance caused by downregulation of the insulin receptor itself will decrease insulin signaling at all steps within the cell, whereas alterations in a single IRS protein will alter only those pathways downstream of that specific IRS protein.
Alterations in Insulin Signaling in a Mouse Model of Insulin Resistance
The leptin-deficient ob/ob mouse is a well-established model of insulin resistance. The absence of leptin causes these mice to be hyperphagic and have low energy expenditure, resulting in morbid obesity, hyperinsulinemia, and hyperglycemia. ob/ob mice also have massive hepatic steatosis and increased very-low-density lipoprotein (VLDL) secretion (137) . In this model of obesity, insulin resistance is associated with numerous changes in insulin signaling, although the exact nature of these varies between tissues.
In the ob/ob liver, there is a decrease in the expression and phosphotyrosine content of the insulin receptor, IRS-1, and IRS-2 (138, 139) . The stoichiometry of the regulatory PI 3-kinase subunits is altered, with a twofold decrease in p85α, the predominant liver isoform; a ninefold increase in p55α; and a twofold increase in p50α. These changes are associated with a decrease in IRS-1, IRS-2, and phosphotyrosine-associated PI 3-kinase activity and Akt phosphorylation (139) . Nonetheless, atypical PKC becomes activated to a similar extent (141) , and basal ERK1 phosphorylation is greatly increased (140) .
SREBP-1c is also increased in the livers of ob/ob mice, producing steatosis and increased triglyceride secretion (127, 137, 142) . This is in contrast to LIRKO mice, which have a decrease in SREBP-1c, VLDL secretion, and hepatic triglyceride accumulation (6a; S.B. Biddinger & C.R. Kahn, unpublished results). Thus, in the insulin-resistant ob/ob liver, there is decreased signaling through PI 3-kinase and Akt, increased activity of SREBP-1c, and dysregulated activity of ERK1.
Unlike the liver, the adipose tissue of ob/ob mice becomes resistant to the effects of insulin on lipogenesis (143) . Consistent with this, SREBP-1c and lipogenic gene expression is markedly reduced in the adipose tissue of ob/ob mice (142) . That ob/ob mice have large, triglyceride-laden adipocytes suggests the importance of processes other than de novo lipogenesis in determining fat cell size, such as increased uptake and/or decreased release of free fatty acids and triglycerides.
In muscle, ob/ob mice also have a decrease in insulin receptor, IRS-1 and IRS-2 protein levels, and phosphotyrosine content (139) . They also have decreases in IRS-1, IRS-2, and phosphotyrosine-associated PI 3-kinase activities (139) . However, there is no decrease in the activation of atypical PKCs, nor are there any changes in the distribution of the isoforms of the regulatory subunits of PI 3-kinase (139, 141) .
By contrast, in retinal vasculature, none of the components of the proximal insulin signaling cascade are downregulated. Thus, there are normal levels of tyrosine-phosphorylated insulin receptor, IRS-1, and IRS-2 (140). Interestingly, Akt phosphorylation is decreased, while ERK1 phosphorylation remains brisk (140) . These changes in the retinal vasculature are associated with increased expression of VEGF, which can directly stimulate neovascularization, and decreased expression of the vasodilator, eNOS (140) . Similarly, the vasculature of the Zucker fa/fa rat, a related model with a defect in the leptin receptor, also has increased MAPK signaling (144) .
In addition, different models of insulin resistance are associated with different defects in insulin signaling. In the high fat-fed rat, for example, IRS-1-and IRS-2-associated PI 3-kinase are increased two-to threefold in liver but decreased in muscle and fat (145) . On the other hand, insulin resistance induced by dexamethasone treatment is associated with IRS-1 and PI 3-kinase levels that are increased 146 BIDDINGER KAHN in liver but decreased in muscle; however, IRS-1-associated PI 3-kinase activity is decreased in both tissues (146) .
Alterations in Insulin Signaling in Human Insulin Resistance
It is much more difficult to study insulin signaling in humans, but in both humans and rodents, different pathways do vary in the degree of insulin resistance they manifest.
In obesity, it has been well established that there is a decrease in insulin receptor binding and a decrease in the phosphorylation of the insulin receptor and IRS-1 in muscle (147) . There is also a dramatic decrease in insulin-stimulated IRS-1-associated PI 3-kinase activity and glucose uptake (147) (148) (149) . However, there is no decrease in the activation of Akt or MAPK (147, 149) . Even more profound defects in IRS-1 phosphorylation and activation of PI 3-kinase are seen in patients with type 2 diabetes; however, activation of Akt and MAPK is still normal (147, 149) . Thus, muscle insulin resistance associated with obesity and type 2 diabetes Figure 9 The insulin resistance syndrome can be produced by either insulin resistance (A) or excessive insulin action (B) in different tissues. The knockout models reveal that insulin resistance in either muscle or brain produces obesity and dyslipidemia, whereas insulin resistance in the liver and β-cell produces glucose intolerance. By contrast, excessive insulin signaling in the liver or endothelium produces dyslipidemia, whereas excessive insulin action in fat produces obesity, glucose intolerance, and dyslipidemia. is associated with a dramatic decrease in signaling through IRS-1 and PI 3-kinase, while signaling through MAPK is maintained.
In human obesity, adipose tissue shows a decrease in 2-deoxyglucose uptake, both basally and following insulin stimulation (151, 152) . Some studies show that adipocytes from patients with obesity or type 2 diabetes also have a decrease in the number of insulin receptors per cell (152) (153) (154) , whereas others show no change (155, 156) . In addition, adipocytes from obese individuals show a decrease in insulin receptor tyrosine kinase activity and IRS-1-associated PI 3-kinase activity; however, IRS-2-associated PI 3-kinase activity is maintained at normal levels (155, 152) . In liver, on the other hand, there is essentially no change in the number of insulin receptors per hepatocyte, insulin receptor kinase activity, and the ability of insulin to inhibit glycogenolysis (152, 157) .
Implications for Human Disease
The insulin resistance syndrome, a constellation of symptoms including dyslipidemia, hypertension, glucose intolerance, and obesity, can progress to diabetes, cardiovascular disease, cancer, nonalcoholic fatty liver disease, and PCOS. These disorders are all related to insulin resistance, but the pathophysiological links between them are not clear.
Insulin resistance is frequently measured and thought of synonymously with impaired glucose uptake. However, using targeted ablations of the insulin receptor and its downstream signaling molecules, we see that the phenotypic manifestations of the insulin resistance syndrome are not always associated with defects in glucose uptake. For example, insulin resistance in fat greatly diminishes glucose uptake into fat tissue but improves overall glucose homeostasis and the serum lipid profile as well as preventing obesity. Similarly, insulin resistance in brain can produce obesity, hyperinsulinemia, and elevated triglycerides, even though the brain is not a site of insulin-stimulated glucose uptake. Thus, defining insulin resistance in terms of decreased glucose uptake may limit our ability to relate insulin resistance to the various components and sequelae of the insulin resistance syndrome.
Tissue-specific knockouts of the insulin receptor also highlight the fact that either insulin resistance ( Figure 9A ) or excessive insulin action ( Figure 9B ) may have detrimental effects. Thus, both insulin resistance in the brain or excessive insulin signaling in fat may produce similar features of the insulin resistance syndrome. Alternatively, mixed insulin sensitivity and resistance in the liver-that is, decreasing activation of Akt and the ability of insulin to suppress glucose production, while increasing activation of SREBP-1c and lipogenesis-may produce glucose intolerance and hepatic steatosis.
Depending on which tissues and pathways are affected, the phenotype of insulin resistance could vary. We could imagine, for example, that if insulin resistance occurred in both the muscle and the fat, the beneficial effects of fat insulin resistance would balance the negative effects of muscle insulin resistance, and disease would be averted. If, instead, insulin resistance in the liver or brain were coupled with a defect in β-cell insulin signaling, diabetes might result. On the other hand, insulin resistance in the brain coupled with continued insulin signaling in the vasculature might promote cardiovascular disease.
Thus, it may be more useful to define and consider insulin resistance in terms of the tissues and pathways in which insulin signaling has been altered. Ultimately, we hope to classify insulin-resistant individuals on the basis of the specific lesions they harbor. By doing so, we may be able to identify better the components and sequelae of the insulin resistance syndrome for which they are most at risk and intervene with more rational therapy. For example, individuals known to have β-cell insulin resistance may be at greater risk for the development of diabetes and may benefit from early institution of insulin therapy. By contrast, therapy for individuals with excess insulin signaling in fat might be directed toward decreasing insulin levels.
CONCLUSIONS
Insulin resistance is a central feature of the insulin resistance syndrome, which manifests itself initially as obesity, glucose intolerance, dyslipidemia, and hypertension but can progress to type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease, and other disorders. Mice harboring tissue-specific knockouts of the insulin receptor and targeted ablations of the insulin signaling molecules have given us powerful insights into the nature of insulin resistance. The heterogeneity of phenotypes expressed by these mice suggests that the diverse presentations of insulin resistance in humans may be due to differences in the pathways and tissues that are defective in insulin signaling. These mice also show us that defects in insulin signaling are not always detrimental and may, in fact, be protective against some features of the insulin resistance syndromes. Furthermore, these mice give us new tools with which to deconstruct the insulin resistance syndromes and to distinguish those tissues and processes that have become resistant from those that have remained sensitive. Such insights no doubt will lead to important advances in the understanding and treatment of these disorders.
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